These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36752971)

  • 1. Impact of urine cyclic AMP relative to plasma arginine vasopressin on response to tolvaptan in patients with chronic kidney disease and heart failure.
    Kakeshita K; Koike T; Imamura T; Fujioka H; Yamazaki H; Kinugawa K
    Clin Exp Nephrol; 2023 May; 27(5):427-434. PubMed ID: 36752971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response Prediction and Influence of Tolvaptan in Chronic Heart Failure Patients Considering the Interaction of the Renin-Angiotensin-Aldosterone System and Arginine Vasopressin.
    Kadota M; Ise T; Yagi S; Iwase T; Akaike M; Ueno R; Kawabata Y; Hara T; Ogasawara K; Bando M; Bando S; Matsuura T; Yamaguchi K; Yamada H; Soeki T; Wakatsuki T; Sata M
    Int Heart J; 2016 Jul; 57(4):461-5. PubMed ID: 27357439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered arginine vasopressin-cyclic AMP-aquaporin 2 pathway in patients with chronic kidney disease.
    Kakeshita K; Koike T; Imamura T; Fujioka H; Yamazaki H; Kinugawa K
    Clin Exp Nephrol; 2022 Aug; 26(8):788-796. PubMed ID: 35503490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure.
    Imamura T; Kinugawa K
    Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26784173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
    Katsumata M; Hirawa N; Sumida K; Kagimoto M; Ehara Y; Okuyama Y; Fujita M; Fujiwara A; Kobayashi M; Kobayashi Y; Yamamoto Y; Saka S; Yatsu K; Fujikawa T; Toya Y; Yasuda G; Tamura K; Umemura S
    Clin Exp Nephrol; 2017 Oct; 21(5):858-865. PubMed ID: 28190113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure.
    Imamura T; Kinugawa K; Fujino T; Inaba T; Maki H; Hatano M; Yao A; Komuro I
    Circ J; 2014; 78(9):2240-9. PubMed ID: 24954239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Lanfear DE; Sabbah HN; Goldsmith SR; Greene SJ; Ambrosy AP; Fought AJ; Kwasny MJ; Swedberg K; Yancy CW; Konstam MA; Maggioni AP; Zannad F; Gheorghiade M;
    Circ Heart Fail; 2013 Jan; 6(1):47-52. PubMed ID: 23239836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peak Lag Between Plasma Vasopressin and Urine Aquaporin-2 Following Cardiac Surgery.
    Yokoyama S; Imamura T; Yamashita S; Doi T; Fukahara K; Yoshimura N; Kinugawa K
    Int Heart J; 2021 Sep; 62(5):1057-1061. PubMed ID: 34544990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease.
    Imamura T; Kinugawa K; Shiga T; Kato N; Muraoka H; Minatsuki S; Inaba T; Maki H; Hatano M; Yao A; Kyo S; Nagai R
    Circ J; 2013; 77(2):397-404. PubMed ID: 23131721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size.
    Toda H; Nakamura K; Nakahama M; Wada T; Watanabe A; Hashimoto K; Terasaka R; Tokioka K; Nishii N; Miyoshi T; Kohno K; Kawai Y; Miyaji K; Koide Y; Tachibana M; Yoshioka R; Ito H;
    J Cardiol; 2016 Feb; 67(2):177-83. PubMed ID: 26072263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolvaptan Prolongs Blockage of the Vasopressin Type II Receptor Over 24 Hours in Responders With Stage D Heart Failure.
    Imamura T; Kinugawa K; Komuro I
    Int Heart J; 2016; 57(1):41-6. PubMed ID: 26742881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: a retrospective, observational study.
    Iwatani H; Kawabata H; Sakaguchi Y; Yamamoto R; Hamano T; Rakugi H; Isaka Y
    Nephron; 2015; 130(1):8-12. PubMed ID: 25926290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure.
    Ikeda S; Ohshima K; Miyazaki S; Kadota H; Shimizu H; Ogimoto A; Hamada M
    ESC Heart Fail; 2017 Nov; 4(4):614-622. PubMed ID: 29154417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
    Onogawa T; Sakamoto Y; Nakamura S; Nakayama S; Fujiki H; Yamamura Y
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S67-76. PubMed ID: 22120095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
    Tominaga N; Kida K; Matsumoto N; Akashi YJ; Miyake F; Kimura K; Shibagaki Y
    Clin Nephrol; 2015 Jul; 84(1):29-38. PubMed ID: 25997504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.
    Kramers BJ; van Gastel MDA; Boertien WE; Meijer E; Gansevoort RT
    Am J Kidney Dis; 2019 Mar; 73(3):354-362. PubMed ID: 30578153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure.
    Otsuka T; Sakai Y; Ohno D; Murasawa T; Sato N; Tsuruoka S
    Clin Exp Nephrol; 2013 Dec; 17(6):834-8. PubMed ID: 23483323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
    Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
    Am J Nephrol; 2017; 46(5):417-426. PubMed ID: 29130954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
    Morooka H; Iwanaga Y; Tamaki Y; Takase T; Akahoshi Y; Nakano Y; Fujiki H; Miyazaki S
    Circ Heart Fail; 2012 Jul; 5(4):484-92. PubMed ID: 22628529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.